Novabay Pharmaceuticals Inc.
13F holders, Q2 2024 (June 30)8holders
$2.21avg. 13F price*
At the end of Q2 2024, 8 institutions reported holding Novabay Pharmaceuticals Inc. in their 13F filings. The largest holders were UBS Group AG ($18K), Tower Research Capital LLC (TRC) ($7K) and Bank of America Corp. ($94).
- Company
- Novabay Pharmaceuticals Inc.
- CUSIP
- 66987P409
- Latest filing quarter
- Q4 2025
History
Number of 13F holders
Total Exit/New Position Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 9 | $25K |
| Exits | 0 | $0 |
Ownership 8 holders
| UBS Group AG | 0.00% | New | 8,158 | $18K |
| Tower Research Capital LLC (TRC) | 0.00% | New | 3,293 | $7K |
| Bank of America Corp. | 0.00% | New | 42 | $94 |
| Morgan Stanley | 0.00% | New | 3 | $7 |
| Nvwm, LLC | 0.00% | New | 3 | $7 |
| Addison Advisors LLC | 0.00% | New | 1 | $3 |
| Northwestern Mutual Wealth Management Co. | 0.00% | New | 1 | $2 |
| Royal Bank of Canada | 0.00% | New | 1 | $0 |
"% of holder's portfolio" is NOVABAY PHARMACEUTICALS INC's weight in each manager's 13F, not the share of Novabay Pharmaceuticals Inc. the manager owns.